Floatz logo

Remimazolam

Major Depressive Disorder

Yeongseok YunSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

197 Active assets in the Major Depressive Disorder cohort.

Asset / SponsorPhaseRating
Selegiline
Corium Innovations, Inc.
Phase 4BBB
Risperidone
Johns Hopkins University
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
Vortioxetine
Mayo Clinic
Phase 4BBB
Brexpiprazole
Nova Scotia Health Authority
Phase 4BBB

View all 50 →

Same molecule, other indications

Remimazolam is also rated in:

schizophreniaActive
BB
Indicative · Phase 4
69 / 100
View asset →
bipolar disorderActive
BB
Indicative · Phase 4
69 / 100
View asset →
osteoarthritis, kneeActive
BB
Indicative · Phase 4
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →